Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors
© 2023 The Authors..
Background & Aims: There is concern about the burden of liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs).
Methods: In a retrospective cohort study, we evaluated the likelihood of grade 3/4 liver injury, of grade 3/4 cholestatic liver injury, and of liver failure, as per the Common Terminology Criteria for Adverse Events (CTCAE) version 5, following treatment with ICIs. We compared these occurrences with a group of cancer patients who were propensity-matched and treated with conventional chemotherapy. For all ICI patients experiencing grade 3/4 liver injury, we conducted a causality assessment using the RUCAM method and examined patient outcomes.
Results: Among 952 patients (median [IQR] age 66 [57-73] years, 64% males) who were treated with ICI between January 1, 2015, and December 31, 2019, a total of 86 (9%) progressed to grade 3/4 liver injury, and liver failure was not observed. Anti-PD-(L)1/anti-CTLA-4 antibodies combinations (adjusted hazard ratio 3.36 [95% CI: 1.67-6.79]; p <0.001), and chronic hepatitis B (adjusted hazard ratio 5.48 [95% CI: 1.62-18.5]; p = 0.006], were independent risk factors. Liver injury was attributed to ICI treatment in 19 (2.0%) patients. Patients with ICI toxicity typically presented with granulomatous hepatitis or cholangiocyte inflammation. ICI withdrawal was associated with cancer progression and mortality. Re-introduction of ICI was not associated with recurrent grade 3/4 liver injury. Compared with matched patients treated with conventional, non-ICI-based chemotherapy, anti-PD-(L)1/anti-CTLA-4 combinations (p <0.001) and anti-PD-(L)1 monotherapies (p = 0.053) increased the risk of grade 3/4 liver injury and of grade 3/4 cholestatic liver injury, respectively.
Conclusions: An increased risk of grade 3/4 liver injury under anti-PD-(L)1/anti-CTLA-4 antibodies was observed, whereas no substantial increase in the likelihood of liver failure occurred even after treatment reintroduction.
Impact and implications: There is concern about liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). We investigated the burden of grade 3/4 liver injury after treatment with ICIs in a multicentric cohort of patients with cancer. Overall, a 9% incidence of grade 3/4 liver injury was detected after ICIs, and direct ICI hepatotoxicity was demonstrated in 2% of patients. Anti-PD-(L)1/Anti-CTLA-4 antibody combinations, and chronic HBV infection were independent risk factors. ICI withdrawal for grade 3/4 liver injury was associated with cancer progression. Re-introduction of ICI treatment was not associated with recurrent grade 3/4 liver injury.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
JHEP reports : innovation in hepatology - 5(2023), 12 vom: 10. Dez., Seite 100880 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parlati, Lucia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer treatment protocols |
|---|
| Anmerkungen: |
Date Revised 11.12.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jhepr.2023.100880 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365657549 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365657549 | ||
| 003 | DE-627 | ||
| 005 | 20231229123328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhepr.2023.100880 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1227.xml |
| 035 | |a (DE-627)NLM365657549 | ||
| 035 | |a (NLM)38074948 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parlati, Lucia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Background & Aims: There is concern about the burden of liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs) | ||
| 520 | |a Methods: In a retrospective cohort study, we evaluated the likelihood of grade 3/4 liver injury, of grade 3/4 cholestatic liver injury, and of liver failure, as per the Common Terminology Criteria for Adverse Events (CTCAE) version 5, following treatment with ICIs. We compared these occurrences with a group of cancer patients who were propensity-matched and treated with conventional chemotherapy. For all ICI patients experiencing grade 3/4 liver injury, we conducted a causality assessment using the RUCAM method and examined patient outcomes | ||
| 520 | |a Results: Among 952 patients (median [IQR] age 66 [57-73] years, 64% males) who were treated with ICI between January 1, 2015, and December 31, 2019, a total of 86 (9%) progressed to grade 3/4 liver injury, and liver failure was not observed. Anti-PD-(L)1/anti-CTLA-4 antibodies combinations (adjusted hazard ratio 3.36 [95% CI: 1.67-6.79]; p <0.001), and chronic hepatitis B (adjusted hazard ratio 5.48 [95% CI: 1.62-18.5]; p = 0.006], were independent risk factors. Liver injury was attributed to ICI treatment in 19 (2.0%) patients. Patients with ICI toxicity typically presented with granulomatous hepatitis or cholangiocyte inflammation. ICI withdrawal was associated with cancer progression and mortality. Re-introduction of ICI was not associated with recurrent grade 3/4 liver injury. Compared with matched patients treated with conventional, non-ICI-based chemotherapy, anti-PD-(L)1/anti-CTLA-4 combinations (p <0.001) and anti-PD-(L)1 monotherapies (p = 0.053) increased the risk of grade 3/4 liver injury and of grade 3/4 cholestatic liver injury, respectively | ||
| 520 | |a Conclusions: An increased risk of grade 3/4 liver injury under anti-PD-(L)1/anti-CTLA-4 antibodies was observed, whereas no substantial increase in the likelihood of liver failure occurred even after treatment reintroduction | ||
| 520 | |a Impact and implications: There is concern about liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). We investigated the burden of grade 3/4 liver injury after treatment with ICIs in a multicentric cohort of patients with cancer. Overall, a 9% incidence of grade 3/4 liver injury was detected after ICIs, and direct ICI hepatotoxicity was demonstrated in 2% of patients. Anti-PD-(L)1/Anti-CTLA-4 antibody combinations, and chronic HBV infection were independent risk factors. ICI withdrawal for grade 3/4 liver injury was associated with cancer progression. Re-introduction of ICI treatment was not associated with recurrent grade 3/4 liver injury | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer treatment protocols | |
| 650 | 4 | |a Drug-induced Liver Injury | |
| 650 | 4 | |a Hepatitis | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 700 | 1 | |a Sakka, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Retbi, Aurelia |e verfasserin |4 aut | |
| 700 | 1 | |a Bouam, Samir |e verfasserin |4 aut | |
| 700 | 1 | |a Hassani, Lamia |e verfasserin |4 aut | |
| 700 | 1 | |a Meritet, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Rufat, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Bonnefont-Rousselot, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Batista, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Terris, Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Bellanger, Agnès |e verfasserin |4 aut | |
| 700 | 1 | |a Thabut, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Vozy, Aurore |e verfasserin |4 aut | |
| 700 | 1 | |a Spano, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Coriat, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Goldwasser, François |e verfasserin |4 aut | |
| 700 | 1 | |a Aractingi, Selim |e verfasserin |4 aut | |
| 700 | 1 | |a Sogni, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Pol, Stanislas |e verfasserin |4 aut | |
| 700 | 1 | |a Mallet, Vincent |e verfasserin |4 aut | |
| 700 | 0 | |a CERTIM Research Group |e verfasserin |4 aut | |
| 700 | 0 | |a DEMOSTHENES Research Group |e verfasserin |4 aut | |
| 700 | 1 | |a Alexandre, Jérôme |e investigator |4 oth | |
| 700 | 1 | |a Arrondeau, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Boudou-Rouquette, Pascaline |e investigator |4 oth | |
| 700 | 1 | |a De Percin, Sixtine |e investigator |4 oth | |
| 700 | 1 | |a Kramkimel, Nora |e investigator |4 oth | |
| 700 | 1 | |a Huillard, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Chapron, Jeanne |e investigator |4 oth | |
| 700 | 1 | |a Deau-Fischer, Benedicte |e investigator |4 oth | |
| 700 | 1 | |a Brandely-Piat, Marie-Laure |e investigator |4 oth | |
| 700 | 1 | |a Damotte, Diane |e investigator |4 oth | |
| 700 | 1 | |a Lupo, Audrey |e investigator |4 oth | |
| 700 | 1 | |a Alifano, Marco |e investigator |4 oth | |
| 700 | 1 | |a Corouge, Marion |e investigator |4 oth | |
| 700 | 1 | |a Hollande, Clémence |e investigator |4 oth | |
| 700 | 1 | |a Fontaine, Hélène |e investigator |4 oth | |
| 700 | 1 | |a Mehiri, Lorianne Lair |e investigator |4 oth | |
| 700 | 1 | |a Pichard, Anaïs Vallet |e investigator |4 oth | |
| 700 | 1 | |a Tilleul, Patrick |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t JHEP reports : innovation in hepatology |d 2019 |g 5(2023), 12 vom: 10. Dez., Seite 100880 |w (DE-627)NLM306339021 |x 2589-5559 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2023 |g number:12 |g day:10 |g month:12 |g pages:100880 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jhepr.2023.100880 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2023 |e 12 |b 10 |c 12 |h 100880 | ||